Given that our work aims to answer some key questions regarding the previously unknown process of the functional commitment of CD8+ T cells induced by mRNA-LNP vaccination, and provide molecular and cellular basis for the improvement of its anti-tumor efficiency; therefore, we chose the most representative mRNA vaccine delivery system based on DLin-MC3-DMA, which is the first approved RNA delivery vector by FDA28, and we believe it can provide more convincing data and is of considerable referential importance for mRNA vaccine mechanistic research. The gene discussed is CD8A; the disease is neoplasm.